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Pancreatic cancer has one of the highest mortalities among all malignancies and there is an urgent need for new therapy. This might
be achieved by resolving the detailed biological mechanism, and in this study we examined how pancreatic cancer cells develop
aggressive properties by focusing on signalling through the fibroblast growth factor (FGF)10 and FGF receptor (FGFR)2, which play
important roles in pancreatic organogenesis. Immunostaining of pancreatic cancer tissues showed that FGFR2 was expressed in
cancer cells, whereas FGF10 was expressed in stromal cells surrounding the cancer cells. Patients with high FGFR2 expression in
cancer cells had a shorter survival time compared to those with low FGFR2 expression. Fibroblast growth factor 10 induced cell
migration and invasion of CFPAC-1 and AsPC-1 pancreatic cancer cells through interaction with FGFR2-IIIb, a specific isoform of
FGFR2. Fibroblast growth factor 10 also induced expression of mRNA for membrane type 1-matrix metalloproteinase (MT1-MMP)
and transforming growth factor (TGF)-b1, and increased secretion of TGF-b1 protein from these cell lines. These data indicate that
stromal FGF10 induces migration and invasion in pancreatic cancer cells through interaction with FGFR2, resulting in a poor prognosis.
This suggests that FGF10/FGFR2 signalling is a promising target for new molecular therapy against pancreatic cancer.
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Pancreatic cancer has one of the highest mortalities among all
malignancies, and is the fourth most common cause of cancer
death in the United States and the fifth in Japan (Li et al, 2004;
Willett et al, 2005). Although significant advances are now being
made into the management of the disease, the 5-year survival rate
still remains poor (Willett et al, 2005; Ghaneh et al, 2007).
Therefore, there is an urgent need for new therapies for pancreatic
cancer, based on an improved understanding of the molecular
biology of the disease. The high mortality rate of pancreatic cancer
is, in part, owing to difficulties of early diagnosis, the high
incidence of metastatic disease at the time of diagnosis, and rapid
progression of the disease. In addition, although newer adjuvant
modalities are greatly increasing the prognosis (Ghaneh et al,
2008), most patients who undergo the surgery eventually relapse
and die of the disease, even with curative resection (Li et al, 2004;
Willett et al, 2005).
An understanding of the mechanisms underlying the biological
aggressiveness of pancreatic cancer may be key for development of
new therapies. Therefore, in this study we examined the molecular
mechanisms underlying cellular invasion and metastasis of
pancreatic cancer cells. Cellular and genetic studies have shown
that tumour growth is not determined by malignant cancer cells
alone, but also by cells in the tumour stroma. Supply of oxygen and
nutrients by endothelial cells of blood vessels are critical for
maintenance of the tumour microenvironment, and stromal
fibroblasts are the principal source of extracellular matrix, which
serves as a scaffold for cancer cells (Kalluri and Zeisberg, 2006).
In addition, recent studies have revealed more active roles
of stromal cells in tumour initiation and progression through
direct interaction with tumour cells. For example, stromal
cell-derived factor-1 (SDF-1/CXCL12) released from fibroblasts
promotes cancer cell proliferation through a specific receptor,
CXCR4, in several types of malignancies, including breast
cancer (Orimo et al, 2005) and pancreatic cancer (Koshiba et al,
2000; Marchesi et al, 2004). Immune cells also play important
roles in cancer progression (Pollard, 2004); for example,
tumour-associated macrophages induced by colony-stimulating
factor 1 promote invasiveness of cancer cells (Lin et al,
2001). Given this background, we hypothesized that
stromal cell–cancer cell interactions have an important role in
acquisition of the aggressive character by pancreatic cancer, and
we examined signalling molecules that may be associated with this
mechanism.
The molecular mechanisms underlying carcinogenesis are often
similar to those in organogenesis. Interactions between stromal
and parenchymal cells are important during organ development,
and signals from stromal cells regulate epithelial cell growth and
differentiation in pancreatic development. The classical tissue
recombinant study by Golosow and Grostein (1962) showed that
growth and morphogenesis of the developing pancreas depend on
mesenchymal interactions, and more recently advances in
molecular biology have allowed the molecular basis of this
interaction to be established. We have shown that signals
from endothelial cells and mesenchymal cells surrounding the Revised 7 May 2008; accepted 20 May 2008; published online 1 July 2008
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spancreatic bud are crucial for initiation of pancreatic development
from endoderm (Yoshitomi and Zaret, 2003; Jacquemin et al,
2006). Especially, we found that fibroblast growth factor-10
(FGF10) from mesenchymal cells maintained expression of Ptf1a,
a critical transcription factor for initiation of pancreatic develop-
ment, in pancreatic progenitor cells (Jacquemin et al, 2006). Mice
deficient in FGF10 or the FGF receptor-2 (FGFR2)/IIIb isoform, the
specific receptor for FGF10 (Igarashi et al, 1998), show impaired
pancreatic development (Bhushan et al, 2001; Pulkkinen et al,
2003). However, it is unknown if FGF10/FGFR2-IIIb-signalling is
associated with carcinogenesis in pancreatic cancer. In this study,
we show that FGF10/FGFR2-signalling has an important role in
pancreatic cancer progression, and we suggest that these results
may lead to a new therapy and a better prognosis for patients with
pancreatic cancer.
MATERIALS AND METHODS
Patients and tissue samples
Pancreatic cancer tissues were obtained from 76 pancreatic cancer
patients who underwent curative surgical resection in the
Department of General Surgery, Chiba University Hospital, Chiba,
Japan, from June 2001 to April 2006. All patients were diagnosed
histologically as primary invasive pancreatic ductal carcinoma.
The patient characteristics are summarised in Table 1. The study
protocol was approved by the Ethics Committee of our institute
and written informed consent was obtained from all patients.
Immunohistochemistry
Paraffin-embedded tissues were cut into 4mm serial sections and
deparaffinised. The sections were placed in citrate buffer
(10mmoll
 1 pH 6.0) with 0.2% Tween 20 and boiled in a
microwave oven (two times 6min) to retrieve the antigen. They
were then rinsed and blocked in 10% H2O2 solution with methanol
for 10min. Next, the sections were incubated with goat anti-human
FGF10 polyclonal antibody (R&D Systems, Minneapolis, MN, USA)
at 1:20 dilution, mouse anti-human FGFR2 monoclonal antibody
(R&D Systems) at 1:10 dilution, or rabbit anti-human
CD3 monoclonal antibody (ready-to-use without dilution)
(Thermo Fisher Scientific Anatomical Pathology, Fremont, CA,
USA) overnight at 41C. They were then rinsed in PBS and
incubated for 60min with a secondary antibody labelled with
streptoavidin–biotin–peroxidase for goat polyclonal antibody
(DAKO LSABþt System, DAKO, Glostrup, Denmark), or dextran
polymer-peroxidase for mouse monoclonal antibody (DAKO
EnVisiont System, DAKO). For detection of anti-CD3 antibody,
CSA II biotin-free catalysed amplification system with rabbit link
(DAKO) was used. The bound complex was visualised using
diaminobenzidine liquid chromogen (Dako) and counterstained with
haematoxylin. Goat polyclonal IgG (Santa Cruz Biotechnology. Santa
Cruz, CA, USA) at an optimal dilution was used as a negative control.
Cell lines and culture conditions
AsPC-1 cells were maintained in RPMI-1640 medium (Invitrogen,
Carlsbad, CA, USA) and MIA PaCa-2, PANC-1 and CFPAC-1 cells
Table 1 Characteristics of pancreatic cancer patients in IHC analysis
FGFR2 FGF10
Total Low High P-value Low High P-value
76 37 39 34 42
Sex NS NS
M 4 41 82 6 1 92 5
F 3 21 91 3 1 51 7
Age (years) NS NS
Mean 65.0 65.0 64.5 65.0 64.5
±s.d. ±9.2 ±9.3 ±9.4 ±9.3 ±8.8
Stage NS NS
IA 2 2 0 2 0
IB 2 2 0 2 0
IIA 15 9 6 4 11
IIB 53 22 31 24 29
III 4 2 2 2 2
Histology NS NS
Tubular adenocarcinoma
Well. 7 3 4 4 3
Mod. 47 26 21 19 28
Poor. 13 5 8 9 4
Invasive carcinoma derived from intraductal tumour 422 04
Anaplastic carcinoma 3 1 2 2 1
Adenosquamous carcinoma 2 0 2 0 2
Resection status
Negative 51 26 25 NS 23 29 NS
Positive 25 11 14 12 13
Adjuvant chemotherapy
  21 9 12 NS 9 12 NS
+ 5 52 82 7 2 53 0
Mod¼moderately differentiated; NS¼no significant; Poor¼poorly differentiated; s.d.¼standard deviation; Well¼well differentiated. Patient stage was determined according
to UICC TNM classification.
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swere cultured with DMEM medium (Sigma-Aldrich, St Louis, MO,
USA). All cell lines were incubated in a humidified atmosphere
containing 5% CO2 at 371C. Each medium contained 10% fetal
bovine serum (Invitrogen), 100Uml
 1 penicillin and 0.1mgml
 1
streptomycin sulphate (Sigma-Aldrich).
For some experiments, cells were seeded (1 10
6 cells in 2ml
medium per well) in 6-well plates, and cultured for 24h. Then cells
were cultured with serum-free medium for another 24h and
changed to new serum-free medium with recombinant human
FGF10 (R&D systems) or/and FGFR2-IIIb/IgG Fc Chimera (R&D
systems) for indicated time in each experiments. Cells and medium
were harvested for further experiments.
Transforming growth factor b 1 (TGF-b1) concentration was
measured using Quantikine Human TGF-b1 immunoassay kit
(R&D systems).
Reverse transcription–PCR
Total RNA was extracted from cultured cells, pancreatic cancer
tissues and adjacent normal tissues with an RNeasy Mini Kit
(QIAGEN GmbH, Hilden, Germany), according to the manufac-
turer’s instructions. cDNA was synthesised from 1mg of total RNA
with SuperScriptt III First-Strand Synthesis SuperMix for reverse
transcription (RT)–PCR (Invitrogen). Polymerase chain reaction
was performed with the following primer sets: FGF10, forward
5-ACATTGTGCCTCAGCCTTTC-3, reverse 5-CCCCTTCTTGTT
CATGGCTA-3; FGFR2-IIIb, forward 5-TATATAGGGCAGGCAAC
CA-3, reverse 5-GCTGAAGTCTGGCTTCTTGG-3; FGFR2-IIIc, for-
ward 5-GTGCTTGGCGGGTAATTCTA-3, reverse 5-GCTGAAGTCT
GGCTTCTTGG-3; and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), forward 5-GTCAGCCGCATCTTCTTTTG-3, reverse
5-TTCACACCCATGACGAACAT-3. The RT–PCR conditions for
FGF10, FGFR2-IIIb, FGFR2-IIIc and GAPDH were as follows: 941C
for 2min, 40 cycles at 941C for 15s, 581C for 30s, and 721C for 30s,
with an extension step of 7min at 721C at the end of the last cycle.
Quantitative RT–PCR
Quantitative RT–PCR was performed as described previously
(Mitsuhashi et al, 2003). Primers for 18 genes related to cancer
invasion and motility have been described by Ide et al (2006). The
mRNA levels of these genes (E-Cadherin, N-Cadherin, Snail,
MMP-1, MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-2, uPA,
TGF-b1, HGF, c-Met, RhoA, CD44, Integrin-a4, Integrin-b4, and
VEGF-A) were determined as the absolute number of copies
normalised against the GAPDH mRNA copy number (Mitsuhashi
et al, 2003). These experiments were performed three times
independently.
Cell migration assay
A migration assay was performed in 12-well plates using a
Quantitative Cell Migrationt Assay Kit (Chemicon International,
Temecula, CA, USA) with an 8.0mm pore size collagen-coated
chamber membrane. The cells were seeded (1 10
5cells in 0.3ml
of serum-free medium) in the upper chamber and cultured for 24h
for attachment. The medium was then replaced by fresh serum-
free medium for another 24h, before addition of recombinant
human FGF10 (100ngml
 1) (R&D Systems) to the lower chamber.
In some experiments, recombinant human FGFR2-IIIb/IgG Fc
Chimera (500ngml
 1) (R&D Systems) was also added to the
lower chamber. The cells were incubated for 12h and the
number of cells that passed through the membrane was counted
according to the manufacturer’s instructions. All experiments
were performed in triplicate and independently at least three
times.
Cell invasion assay
An invasion assay was performed in 24-well plates using a BD
Biocoatt Matrigelt Invasion Chamber (BD Biosciences, Bedford,
MA, USA) with an 8.0mm. pore size polyethylene terephthalate
(PET) membrane coated with Matrigel. The inserts were rehy-
drated by adding 0.5ml of warm culture medium at 371C for 2h.
The cells were seeded (5 10
5cells in 0.5ml of serum-free
medium) in the upper chamber and cultured as described in the
method for the migration assay. The number of seeded cells,
culture conditions and other items were also similar to those for
the migration assay. The cells were incubated for 24h and the
number of cells that passed through the membrane was counted
according to the manufacturer’s instructions. All experiments were
performed in triplicate and independently at least three times.
Statistical analysis
Values are expressed as means±s.d. The distribution of catego-
rical data for FGFR2 immunostaining in tissue samples and for
clinicopathological characteristics were assessed by a w
2 test and a
Fisher’s exact test. Survival time was calculated using the Kaplan–
Meier method and compared by log-rank test. Cell migration and
cell invasion data were analysed using a Student’s t-test and a
Mann–Whitney U-test. Statistical significance was assumed for
Po0.05.
RESULTS
Expression of FGFR2 in pancreatic cancer cells and FGF10
in cancer stromal cells
To examine the expression pattern of FGFR2 and FGF10 in
pancreatic cancer tissues, we performed immunohistochemical
staining of 76 tissue samples of invasive pancreatic ductal
carcinoma and of normal pancreatic tissues. FGF receptor-2
immunoreactivity was weak to moderate in pancreatic ductal cells
in normal tissues (Figure 1A; arrow) and acinar cells (Figure 1A;
arrowhead), as well as in islet cells (data not shown), as described
previously (Ishiwata et al, 2002). On the other hand, immuno-
staining of FGF10 did not occur in normal pancreatic tissue, as also
described previously (Ishiwata et al, 2002) (Figure 1B).
In pancreatic cancer tissues, cancer cells expressed FGFR2 at
various levels (Figure 1C), but did not express FGF10 (Figure 1D).
Pancreatic cancer tissue often contains a few islet cells (Figure 1E
and 1F; arrowheads) and we compared the expression levels of
FGFR2 in cancer cells and islets. In 39 cases (51.3%), FGFR2
immunoreactivity in cancer cells was stronger than in islets (high
expression group, Figure 1E). In the other 37 cases (48.7%), FGFR2
immunoreactivity was not found or was faint in cancer cells, and
was weaker than in normal islet cells (low expression group,
Figure 1F). There was no correlation between FGFR2 immuno-
reactivity levels and tumour histological findings (Table 1).
Pancreatic cancer cells did not express FGF10 in any samples
(Figure 1D), but scattered cells in stroma surrounding the cancer
cells showed strong expression of FGF10 (Figure 1D; arrows).
Fibroblast growth factor 10-positive stromal cells in cancer tissues
were found in 42 cases (55.3%), and interestingly, were mainly
localised close to cancer cells (Figure 1D and 1E). Moreover, of the
42 cancer tissue samples with FGF10-positive stromal cells, 29
(69.0%) showed high FGFR2 expression in cancer cells, and there
was a significant correlation between the presence of FGF10-
positive stromal cells and high FGFR2 expression in cancer cells
(P¼0.013).
Next we examined which kind of cancer stromal cells expressed
FGF10. We stained sequential sections with antibody against
FGF10 and stromal cell markers (CD68; macrophage marker,
a-smooth muscle actin; activated fibroblast marker, CD3; T-cell
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smarker). Within them, CD3-positive stromal cells, T-cells, were
located similar to FGF10-positive stromal cells and also has similar
cell shapes (Figure 1G and 1H; arrows). However, due to the
technical difficulties, we could not demonstrate that FGF10-
expressing cells were identical with T-cells.
Overall, the results show that FGFR2 is expressed in pancreatic
cancer tissue, and that its ligand, FGF10, is expressed in stromal
cells.
FGFR2 expression levels correlates with prognosis of
pancreatic cancer patients
Next, we examined whether strong expression of FGFR2 in cancer
cells correlated with patient prognosis. The 76 patients were
divided into two groups according to the expression level of FGFR2
in cancer cells (the high and low expression groups in Table 1).
The expression level of FGFR2 was not correlated with
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Figure 1 Expression patterns of FGFR2 and FGF10 in normal pancreas and pancreatic cancer. The magnification is shown in the right bottom corner of
each figure. (A and B) Immunostaining of FGFR2 (A) and FGF10 (B) in normal pancreas, showing that FGFR2 is expressed weakly in ductal cells (A, arrow)
and acinar cells (A, arrow head), and that no obvious FGF10 staining is found in normal pancreatic tissue, including ductal cells (B, arrows). (C and D)
Immunostaining of FGFR2 (C) and FGF10 (D) in pancreatic cancer tissues, showing that FGFR2 is expressed in cancer cells (C), whereas FGF10 is expressed
in scattered cells in the stroma surrounding cancer cells (D, arrows). (E and F) Immunostaining of FGFR2 in pancreatic cancer cells. (E) Representative result
from the FGFR2 high expression group, indicating higher FGFR2 expression in cancer cells (arrows) compared with islets (arrow head). (F) Representative
result from the FGFR2 low expression group, showing lower FGFR2 expression in cancer cells (arrows) compared with islet (arrow heads). (G and H)
Immunostaining of FGF10 (G) and CD3 (H), marker for T cell. Fibroblast growth factor 10 and CD3 are both expressed in scattered cells with similar cell
shape in the stroma surrounding cancer cells (arrows).
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sclinicopathological factors such as sex, age and pathological stage
(Table 1). There were no statistical differences in the resection
status of both groups. Also, the ratios of patients who received
adjuvant chemotherapy (using gemcitabine) were similar in both
groups, indicating that patients in both groups were treated with
similar therapeutic approaches after surgery (Table 1). Interest-
ingly, Kaplan–Meier analysis showed that patients with high
FGFR2 expression had a significantly shorter overall survival time
compared to those with low expression levels (Figure 2) (P¼0.047
by log-rank test). Moreover, patients with high FGFR2 expression
had significantly more nodal invasion, a larger tumour size, and a
worse UICC Stage (Table 2; P¼0.0263, P¼0.0469, and P¼0.022,
respectively, by w
2-test). There was no significant correlation
between survival time and the presence of FGF10 in stromal cells in
cancer tissue (data not shown).
FGF10/FGFR2-IIIb signalling induces cell migration and
invasion
The expression pattern of FGF10 and FGFR2 in cancerous tissue
and the poor prognosis of patients with high FGFR2 expression in
cancer cells indicate that a stromal cell–epithelial cell interaction
through FGF10/FGFR2 signalling might induce the malignant
properties of pancreatic cancer. To examine this hypothesis, we
analysed the effects of FGF10 on the proliferation, invasion and
migration of pancreatic cancer cells. For this purpose, four
pancreatic cancer cell lines were used: MIA PaCa-2, PANC-1,
CFPAC-1 and AsPC-1 cells.
First, we examined whether these cell lines expressed FGFR2 and
FGF10. Reverse transcriptase–PCR analysis showed that all four
cell lines did not express FGF10 mRNA, consistent with the results
of immunostaining showing FGF10 expression in stromal cells, but
not in cancer cells, in pancreatic cancer tissue (Figure 3A).
Fibroblast growth factor 10 activity is dependent on its binding to
the FGFR2-specific isoform, FGFR2-IIIb (Igarashi et al, 1998).
Therefore, a primer set for FGFR2-IIIb was designed with a 5
primer for its specific exon in the FGFR2 gene. Reverse
transcriptase–PCR analysis with this primer showed that
CFPAC-1 and AsPC-1 cells expressed the FGFR2-IIIb isoform,
whereas the other two cell lines did not do so (Figure 3A).
To examine cancer cell proliferation, the cells were stimulated
with various concentrations of FGF10 (10–200ngml
 1), but no
effect of FGF10 was observed in any of the four cell lines (data not
shown). Next, we examined whether FGF10 affects migration or
invasion of pancreatic cancer cells. Representative results from the
cell migration and invasion assays are shown in Figure 3B.
Interestingly, FGF10 stimulated cell migration and invasion of cells
that expressed FGFR2-IIIb (CFPAC-1 and AsPC-1), but not of cells
without expression of the specific receptor (MIA PaCa-2 and
PANC-1) (Figure 3C and 3D). For CFPAC-1 cells, migration was
almost doubled (Figure 3C) and invasion was increased by 1.5
times (Figure 3D) following stimulation with FGF10 (100ngml
 1).
Similar results were obtained for AsPC-1 cells (Figure 3C and 3D).
To confirm that the effects of FGF10 on pancreatic cells were
mediated through FGFR2-IIIb, we used a molecular hybrid
including the FGFR2-IIIb extracellular domain and the carboxy-
terminal Fc region of human IgG (recombinant human FGFR2-
IIIb/IgG Fc Chimera). Such hybrids inhibit signalling through the
FGFR2-IIIb receptor by antagonising ligand binding (Jung et al,
1999). Stimulated migration of CFPAC-1 cells by 100ngml
 1
FGF10 was completely inhibited by addition of FGFR2-IIIb/IgG Fc
Chimera (500ngml
 1) (Figure 3E; compare the second and third
columns). The effects of the chimera were due to inhibition of
signalling through FGFR2-IIIb, rather than to a direct effect of the
chimera on the cells, as addition of chimera alone did not affect
cell migration (Figure 3E; compare the first and fourth columns).
Invasion of CFPAC-1 cells stimulated by FGF10 was also inhibited
by FGFR2-IIIb/IgG Fc Chimera (Figure 3F). Overall, these results
indicate that FGF10 stimulates migration and invasion of cancer
cells through its specific receptor, FGFR2-IIIb.
Upregulation of MT1-MMP and TGF-b1 mRNA by FGF10
To examine the molecular mechanisms through which FGF10
signalling induces migration and invasion of pancreatic cancer
cells with FGFR2-IIIb expression, we analysed whether FGF10
stimulation induced mRNA expression of 18 genes related to cell
mobility in CFPAC-1 cells (see Materials and methods for the 18
genes). CFPAC-1 cells were cultured with recombinant human
FGF10 (100ngml
 1) for 12, 24 and 48h, and then total RNA were
extracted and the mRNA levels of the 18 genes were analysed by
quantitative RT–PCR. Among these genes, FGF10 upregulated the
expression levels of MT1-MMP (Figure 4A) and TGF-b1
(Figure 4B) mRNAs in a time-dependent manner. In CFPAC-1
cells, the mRNA expression levels for both genes were almost 10
times higher after FGF10 stimulation for 48h compared with the
level before stimulation. The concentration of TGF-b1 in culture
medium was also upregulated in time-dependent manner in
CFPAC-1 cells (Figure 4C) and also in AsPC-1 cells (data not
shown). The secretion of TGF-b1 by FGF10 stimulation in CFPAC-1
cells was inhibited by FGFR2-IIIb/IgG chimera (Figure 4D),
indicating FGF10-induced TGF-b1 secretion through FGFR2.
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Figure 2 Kaplan–Meier survival curves for patients with high and low
FGFR2 expression. Patients with low FGFR2 expression had a significantly
longer overall survival time compared to those with high FGFR2 expression
(Po0.05 by log-rank test).
Table 2 Clinico-pathological features of pancreatic cancer patients in
FGFR2-IHC analysis
FGFR2 expression of IHC
Total Low expression High expression
76 37 39 P-value
T (1,2,3/ 4) 42/34 23/14 19/20 NS
N (0/ 1,2,3) 20/56 14/23 6/33 0.0263
M (0/ 1) 67/9 35/2 32/7 NS
ly (0/ 1,2,3) 14/62 9/28 5/34 NS
v (0/ 1,2,3) 31/45 19/18 12/27 NS
ne (0/ 1,2,3) 11/65 7/30 4/35 NS
Size (o/X; 30mm) 37/39 23/14 14/25 0.022
IA, IB, IIA/IIB, III 19/57 13/24 6/33 0.0469
Poor/others 13/63 8/29 5/34 NS
ly¼lymphatic invasion; M¼distant metastasis; N¼nodal metastasis; ne¼neural
invasion; NS¼no significant; Poor¼poorly differentiated adenocarcinama;
T¼tumour depth; v¼venous invasion. Patient stage was determined according to
UICC TNM classification.
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sDISCUSSION
In this study, we investigated the molecular mechanisms under-
lying the aggressiveness of pancreatic cancer, and found that
FGF10/FGFR2-IIIb-signalling plays an important role in inducing
migration and invasion of pancreatic cancer cells. FGF receptor-2-
IIIb is a splice variant of FGFR2 that is predominantly expressed
by cells of epithelial origin and is involved in proliferation of these
cells, whereas other FGFR2 variant transcripts are detected in
mesenchymal cells (Miki et al, 1992). Ishiwata et al (1998) first
showed that the FGFR2-IIIb isoform of the FGF receptor is
expressed in pancreatic cancer cells. We confirmed this result by
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Figure 3 Fibroblast growth factor 10 induces cell migration and invasion in pancreatic cell lines with FGFR2-IIIb expression. (A) RT–PCR analysis of
FGF10 and FGFR2-IIIb in four pancreatic cell lines and cDNA obtained from normal lung tissue as a positive control. None of the cell lines express FGF10.
MIA PaCa-2 and PanC-1 cells do not express FGFR2-IIIb, but CFPAC-1 and AsPC-1 do express this gene. (B) Representative results of cell migration (upper
panels) and invasion (lower panels) for CFPAC-1 cells. Representative migrated and invaded cells are indicated with arrows. (C and D) Cell migration
(C) and invasion (D) assay of all four cell lines cultured without (white column) or with (black column) FGF10 (100ngml
 1). FGF10-induced cell migration
and invasion in CFPAC-1 and AsPC-1 cells, but not in MIAPaCa-2 and PanC-1 cells. The numbers of migrated or invaded cells cultured with FGF10 are
shown relative to a value of 100% for cell migration without ligand. (E and F) Inhibition of FGFR2-IIIb signalling by an FGFR2-IIIb/IgG chimera in CFPAC-1
cells. Migration (E) and invasion (F) assay. The numbers of migrated or invaded cells are shown relative to a value of 100% for cells cultured without FGF10
or chimera (control; white column). FGF10-induced migration and invasion in CFPAC-1 cells (black column). Addition of the FGFR2-IIIb/IgG chimera
completely eliminated the effects of FGF10 (grey column), whereas the chimera itself did not affect cell migration and invasion of CFPAC-1 cells (striped
column). *Po0.05.
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simmunostaining of 76 resected pancreatic cancer tissues, and
moreover, showed that the expression level of FGFR2-IIIb is
correlated with prognosis and the incidence of nodal involvement.
These findings indicate that signalling through FGFR2-IIIb may
induce malignant potential, and especially, may increase the
metastatic ability of pancreatic cancer cells.
FGFR2-IIIb was first identified as a high-affinity receptor of
FGF7 (keratinocyte growth factor) (Miki et al, 1992), and it can
also be activated by FGF10, which has strong sequence homology
with FGF7 (Igarashi et al, 1998). Our results show that FGF10 is
expressed in stromal cells scattered around pancreatic cancer cells,
suggesting a possible interaction with cancer cells expressing
FGFR2-IIIb. To our knowledge, this is the first report of the
expression pattern of FGF10 in pancreatic cancer. We also show
that FGF10-positive cells and CD3-positive T cells exist in a similar
location and have a similar shape. According to these data, we
hypothesize that FGF10 is expressed in T cells surrounding
pancreatic cancer cells. Supporting this, during wound healing, T
cells bearing gd T cell receptors are an important source of FGF7
and FGF10, which activate epithelial cell proliferation (Jameson
et al, 2002). Further studies are required for confirming this
hypothesis.
Despite the high homology, the function of FGF10 differs slightly
from that of FGF7. We found that FGF10 induced cell migration
and invasion in pancreatic cancer cells, but had no effect on cell
proliferation. Alderson et al (2002) also found that FGF10 does not
affect cell proliferation in several types of cancer cells, whereas Niu
et al (2007) recently showed that FGF7 stimulates cell proliferation,
in addition to cell migration and invasion, in pancreatic ductal
epithelial cells. These two genes also have different expression
patterns in pancreatic cancer. Cho et al (2007) showed that FGF7 is
expressed in pancreatic cancer cells themselves and acts in an
autocrine manner, whereas our results showed FGF10 expression
in stromal cells of pancreatic cancer, indicating a paracrine FGF10/
FGFR2-IIIb interaction. Further studies are required to understand
how these ligands, which share the same receptor on cancer cells,
are orchestrated to induce malignant properties in pancreatic
cancer.
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Figure 4 Fibroblast growth factor 10 induces expression of mRNA for MT1-MMP and TGF-b1 in CFPAC-1 cells. The figure shows the relative copy
numbers of MT1-MMP (A) and TGF-b1( B) mRNA in CFPAC-1 cells cultured with 100ngml
 1 of FGF10 for the indicated times. The MT1-MMP and
TGFb1 mRNA/GAPDH mRNA copy number ratios are shown relative to those of cells without FGF10 stimulation (0h). The concentration of TGF-b1
protein in medium also increased in time-dependent manner in CFPAC-1 cells 48h after addition of FGF10 (100ngml
 1)( C). FGF receptor-2-IIIb/IgG
chimera (500ngml
 1) inhibited this TGF-b1 secretion by FGF10, whereas chimera alone did not affect TGF-b1 secretion by itself (D). *Po0.05; NS=not
significant.
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sTo understand how FGF10/FGFR2-IIIb signalling induces cell
migration and invasion of pancreatic cancer cells, we examined
whether FGF10 influences the expression of genes related to cell
mobility. Interestingly, FGF10 induced expression of membrane
type 1-matrix metalloproteinase (MT1-MMP) and transforming
growth factor (TGF)-b1 mRNA in CFPAC-1 cells, and these genes
may lead, at least in part, to cell migration and invasion of cancer
cells. The metalloproteinases are known to involve cell invasion
ability. Within several types of metalloproteinases and their
i n h i b i t o rt h a tw ee x a m i n e d( M M P - 1 ,2 ,7 ,9 ,M T 1 - M M P ,T I M P - 2 ) ,
only the mRNA expression of MT1-MMP was upregulated by
FGF10 in CFPAC-1 cells. Membrane type 1-matrix metalloprotei-
nase was originally found as a metalloproteinase with a
transmembrane domain in homology screening for the MMP
conserved domain (Sato et al, 1994). The MT1-MMP protein
induces invasive activity by degrading extracellular matrix
surrounding epithelial cells through its proteinase activity, or by
activating other proteinases (Seiki, 2003). In pancreatic cancer,
enhanced MT1-MMP expression is particularly observed in
metastatic lesions (Maatta et al, 2000). These facts may indicate
that induction of MT1-MMP is one of the mechanisms through
which FGF10 induces cell invasion activity. We are trying to
examine if the proteinase activity of MT1-MMP is increased by
FGF10 stimulation in pancreatic cancer cells.
TGF-b1 is also an important regulator of cell invasion and
migration activity, and is frequently overexpressed in pancreatic
cancer, with the expression level associated with an advanced
tumour stage and a poor prognosis (Friess et al, 1993a,b).
Moreover, TGF-b1 is an important regulator of the epithelial
mesenchymal transition, in which epithelial cells disassemble their
junctional structures, start expressing mesenchymal cell proteins,
remodel the extracellular matrix, and become migratory (Moustakas
and Heldin, 2007). As a result, cancer cells acquire metastatic
properties (Oft et al, 1998; McEarchern et al, 2001), suggesting that
FGF10/FGFR2-IIIb-signalling may promote migration of pancrea-
tic cancer cells through induction of TGF-b1 expression. We also
found that FGF10 induced not only mRNA expression of TGF-b1
but also the secretion of this protein through signalling through
FGFR2-IIIb in CFPAC-1 cells. This strongly supports the hypoth-
esis and it should be confirmed in future.
In conclusion, our results indicate an important role for the
interaction between stromal cells and parenchymal cells mediated
by FGF10/FGFR2-IIIb signalling in pancreatic cancer. This
suggests that FGF10 and FGFR2-IIIb are promising candidates as
target molecules for new therapy against pancreatic cancer, and
that therapeutic agents directed against these molecules may
improve the prognosis of patients with this disease.
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